Close Menu

NEW YORK (GenomeWeb) – Australian molecular diagnostics company SpeeDx said it has received a A$2.5 million ($2 million) grant from the New South Wales Medical Devices Fund (MDF) to support the continued rollout of its multiplex molecular diagnostic ResistancePlus MG test.

Separately, it also announced a distribution deal with Scandinavian clinical laboratory supplier Diagen. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.